Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Telix Pharmaceuticals Limited Releases Annual Report Year Ending 2019.
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her position of Telix EU President.
Telix Supports Molecular Imaging Summer Program at MSKCC
Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at MSKCC
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American patients
Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US
With over 15 years of hands-on experience in Diagnostic Imaging and Sales, Robyn will be solidifying our presence in the Western US. Robyn has an extensive background in Diagnostic Imaging including Nuclear Medicine, Positron Emission Tomography (P.E.T.) and Radiologic Technology. She began her career in the clinical setting as a Radiologic Technologist specializing in Computed Tomography (CT), Mammography and expanding her training at Loma Linda Medical University in Nuclear Medicine Technology.
Anthony Zinno, MBA Joins Telix Pharmaceuticals US
With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success has been built on developing and implementing business strategies, scaling and structuring organizations for growth, and developing unified cultures focused on common goals.
NDA Clinical Briefing Package Submitted to the US FDA
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1
ZIRCON Phase 3 IND Submitted to the US FDA
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx
TLX101 for Brain Cancer IPAX-1 Study Update
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research grant